regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
==== Canada ==== In October 2018, cannabidiol became legal for recreational and medical use by the federal Cannabis Act. As of August 2019, CBD products in Canada could only be sold by authorized retailers or federally licensed medical companies, limiting their access to the general public. Nonetheless, with online delivery services and over 2,600 authorized cannabis retail stores as of October 2021, accessibility has steadily increased over time. The Canadian government states that CBD products "are subject to all of the rules and requirements that apply to cannabis under the Cannabis Act and its regulations." It requires "a processing licence to manufacture products containing CBD for sale, no matter what the source of the CBD is, and that CBD and products containing CBD, such as cannabis oil, may only be sold by an authorized retailer or licensed seller of medical CBD." Edible CBD products were scheduled to be permitted for sale in Canada on October 17, 2019, for human consumption. As of August 2020, it was still illegal to carry cannabis and cannabis-derived products (including products containing CBD) across the Canadian border. If one carries any amount of cannabis for any purpose (including medical), it needs to be declared to the Canada Border Services Agency. Not declaring it is a serious criminal offence.
Acapulco, with its natural harbor, had been settled by indigenous peoples for thousands of years and later established as a port by Hernán Cortés in 1523. By Humboldt’s visit, the city had diminished in significance, with a small population and little commercial activity. Upon arrival, Humboldt used his instruments to correct geographic errors caused by local currents and earthquakes, further improving navigation and mapping accuracy. Humboldt’s primary reason for coming to New Spain was to secure passage to the Philippines, but he viewed Mexico as a vital subject for study. At the start of the nineteenth century, New Spain was a populous and prosperous colony, contributing significantly to Spain’s economy through silver, gold, and agricultural production. Humboldt, holding a royal passport, enjoyed unprecedented access to official records and facilities, enabling him to study the country’s economic and political structures thoroughly.
I think "Sickman" is not that bad. I thought most of the hassle would come from "Junkhead" and "Godsmack". Those songs are put in sequence on the second side those five songs from "Junkhead" to "Angry Chair" for a reason: Because it tells a story. It starts out with a really young naive attitude with "Junkhead", like drugs are great, sex is great, rock'n' roll, yeah! Then, as it progresses, there's a little bit of growing up and a little bit of a realization of what it's about, and that ain't what it's about. I've been using this phrase a lot, but it makes a lot of sense: It's really easy to die; it's really hard to live. It takes a lot of guts to live. It doesn't take a lot of guts to die. Those five and "Sickman" are the only ones talking about that type of mentality [drugs]. The rest of the stuff is not like that at all. "Rain When I Die" is a song to a girl. There's a lot of stuff on it. A good portion of it is a story, and it's meant to be that way. It's kind of overwhelming and unpleasant at times, unsettling maybe, but that's why all those songs are together. Even if it's disturbing, it's not something anybody else needs to worry about or the way somebody else needs to live their life. In the liner notes of 1999's Music Bank box set collection, Cantrell cited "Junkhead" and "God Smack" as "the most openly honest" songs about drug use. Cantrell said he wrote "Them Bones" about "mortality, that one of these days we'll end up a pile of bones." He told RIP magazine in 1993: "'Them Bones' is pretty cut and dried.
In addition to other 2Cs, derivatives of 2C-B such as 2C-B-FLY and 25B-NBOMe have been developed and emerged as well-known novel designer drugs. 2C-B-FLY was Ann Shulgin's favorite psychedelic, which she especially enjoyed in terms of enhanced eroticism, and preferred "a bit more" than 2C-B.
Dread Central writer Jay Krieger found that monsters that were "reflective of their singularly unique worlds" were more memorable to him, and felt that there were few better examples of this than the Headcrab. He felt that the zombification they induced was evocative of John Carpenter's The Thing rather than George A. Romero's zombie films. He found the Half-Life 2 iteration of the Headcrab Zombies as particularly shocking, citing how the Headcrab Zombies have muffled screams from the host and, when killed, the Headcrab falls off dead, revealing a face recognizable enough to see the "haunted look of them realizing their fate in their final moments remains". He argued that the zombies of Half-Life served to show the humanity of the Headcrabs' victims. He also believed that the Headcrabs in Ravenholm, particularly the Poison Headcrabs and running zombies, represented how big of a threat Headcrabs could be. Edge staff felt that the running zombie was a memorable video game monster, believing that its "demented wail" was among the most chilling noises in video games. The Headcrab Zombies were described as "walking tragedies" by Rock Paper Shotgun writer Alec Meer, believing that they represented the horror of what zombies are rather than what zombies can do to the player. He appreciated how the game managed to escalate from questioning why the "weak, tiny" Headcrabs were attacking people, to seeing corpses twitching, and finally to seeing someone who was probably still alive but with no control of their body.
Sources: en.wikipedia.org
Venlafaxine has been implicated in causing the most severe withdrawal symptoms after cessation of use, possibly due to its short half-life. To simplify identifying the principal signs and symptoms, the mnemonic FINISH may be used:
==== 2021–present ==== Al-Burhan reinstated the TSC on 11 November 2021 with the same military and rebel members, but with all but one of the civilian members replaced. He left the seat for a civilian representative from Eastern Sudan vacant. The members are:
== Chemistry == The oxidation reaction that converts adrenaline into adrenochrome occurs both in vivo and in vitro. Silver oxide (Ag2O) was among the first reagents employed for this, but a variety of other oxidizing agents have been used successfully. In solution, adrenochrome is pink and further oxidation of the compound causes it to polymerize into brown or black melanin compounds.
== Interactions == Meropenem rapidly reduces serum concentrations of valproic acid. As a result, people who use valproic acid for epilepsy are at increased risk of seizures during treatment with meropenem. In situations where the use of meropenem cannot be avoided, prescription of an additional anticonvulsant should be considered.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.